期刊
LIVER INTERNATIONAL
卷 33, 期 -, 页码 93-104出版社
WILEY
DOI: 10.1111/liv.12076
关键词
asunaprevir; daclatasvir; faldaprevir; simeprevir; NS5A inhibitors; NS5B polymerase inhibitors; protease inhibitors; ribavirin; sofosbuvir
The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response (SVR) rates with oral regimens and shortened treatment duration. Combinations of antivirals with additive potency that lack cross-resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据